Novartis Ag (NVS) Non Operating Interest Expenses (2009 - 2026)

Novartis Ag has disclosed Non Operating Interest Expenses across 18 years of filings, most recently posting -$462.0 million for Q2 2026.

• In Q2 2026, Non Operating Interest Expenses fell 59.86% year-over-year to -$462.0 million; the TTM figure through Jun 2026 stood at -$1.6 billion (down 5.86% YoY), while the FY2025 annual figure was -$1.1 billion, down 13.72% from the prior year.
• Non Operating Interest Expenses came in at -$462.0 million for Q2 2026 at Novartis Ag, down from -$343.0 million in the prior quarter.
• In the past five years, Non Operating Interest Expenses ranged from a high of -$200.0 million in Q1 2023 to a low of -$731.0 million in Q4 2024.
• Average Non Operating Interest Expenses over 5 years is -$341.3 million, with a median of -$267.0 million recorded in 2024.
• Year-over-year, Non Operating Interest Expenses gained 23.53% in 2025 and slumped 59.86% in 2026.
• Over 5 years, Non Operating Interest Expenses stood at -$593.0 million in 2022, then retreated by 7.59% to -$638.0 million in 2023, then fell by 14.58% to -$731.0 million in 2024, then advanced by 23.53% to -$559.0 million in 2025, then increased by 17.35% to -$462.0 million in 2026.
• Per Business Quant data, the three most recent Non Operating Interest Expenses figures were -$462.0 million in Q2 2026, -$343.0 million in Q1 2026, and -$559.0 million in Q4 2025.